Canakinumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Canakinumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
127
Registered trials
210
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Canakinumab can convert its Monoclonal antibody profile and IL-1β biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Canakinumab (query alias: canakinumab) |
|---|---|
| Modality / target | Monoclonal antibody; IL-1β; IL-1β inhibitors |
| Highest global status | Approved |
| Originator | Novartis Pharma AG |
| Active developers | Novartis Pharma AG, Novartis Europharm Ltd., Novartis Pharmaceuticals Canada, Inc. |
The MCP disease footprint includes Schnitzler Syndrome, Gout, Neonatal-Onset Multisystem Inflammatory Disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06691217 | Phase 2 | Recruiting | 120 | Between-group difference (canakinumab versus placebo) in the change in perivascular fat attenuation index (Hounsfield units) measured by coronary computed tomography angiography |
| NCT07138898 | Phase 2 | Recruiting | 80 | Incidence of wound complications |
| NCT06038526 | Phase 2 | Completed | 41 | Change in ASCs (apoptosis-associated speck-like protein containing a caspase activation and recruitment domain) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
CONCOMITANT USE OF CANAKINUMAB MAY LEAD TO STEROID-FREE DOSING OF PEGLOTICASE
Not Applicable; n=63; evaluation: Positive. Reported fields: Gout flares = One patient stated a non-physician observed gout flare that was resolved after a single dose of colchicine and indomethacin. Another patient with a physician witnessed flare occurred at 3 months post canakinumab injection and was successfully treated with a second dose of canakinumab.
Neoadjuvant IL-1β and PD-1 inhibition in localized clear-cell renal cell carcinoma: Clinical and correlative analyses of the phase 1b SPARC-1 trial
Phase 1; n=14; evaluation: Positive. Reported fields: MFS(12-month) = 100.0 %
An Open-label, Single-arm, Active-treatment Study to Evaluate Efficacy and Safety of Canakinumab (ACZ885) Administered for at Least 48 Weeks in Japanese Patients With Adult Onset Still's Disease (AOSD)
Phase 3; n=14; evaluation: not stated. Reported fields: -; -; Percentage of Participants Who Achieved Adapted American College of Rheumatology (ACR) 30 Response at Week 8 = 50.0 Percentage of participants (95% Confidence Interval, 20.2 - 79.8)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Canakinumab addresses Schnitzler Syndrome, Gout, Neonatal-Onset Multisystem Inflammatory Disease. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2009-06-11 | REGENERON CONVERTS INTERLEUKIN-1 ANTIBODY OPT-IN RIGHTS TO ROYALTY AGREEMENT with Novartis | Phase 3 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Use of il-1b binding antibodies for treating neuroinflammatory disorders”. The milestone feed surfaced a patent-application signal described as “Preparation and application of drug balloon with Canakinumab coating”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
